Evidence map›Paper›PMID 42062177›Full record

Trial reportHematological oncology2026

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

H Mocikova, L Gaherova, T Jancarkova, A Suri, A Janikova, K Steinerova, D Belada, R Pytlik, J Duras, M Trnkova and 3 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02777736 (Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02777736 phase3unknown statusnot on this map

Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study

TypeinterventionalSponsorCzech Lymphoma Study GroupRan2015 to 2019Enrolled500ConditionsDiffuse Large B-cell LymphomaArmsMethotrexate
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

H MocikovaDepartment of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
L GaherovaDepartment of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
T JancarkovaDepartment of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
A SuriDepartment of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
A JanikovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
K SteinerovaDepartment of Clinical Hematology, University Hospital, Pilsen, Czech Republic.
D BeladaDepartment of Internal Medicine- Hematology, University Hospital and Faculty of Medicine, Pilsen, Czech Republic.
R PytlikCell Therapy Department, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
J DurasDepartment of Hemato-Oncology, University Hospital and Faculty of Medicine, Ostrava, Czech Republic.
M TrnkovaIst Department of Medicine, General University Hospital, Ist Faculty of Medicine, Charles University, Prague, Czech Republic.
P BlahovcovaDatacenter of the Czech Lymphoma Study Group, Prague, Czech Republic.
T KozakDepartment of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
M TrnenyIst Department of Medicine, General University Hospital, Ist Faculty of Medicine, Charles University, Prague, Czech Republic.ORCID https://orcid.org/0000-0002-6952-6073

Funding

Ministerstvo Zdravotnictví Ceské Republiky AZV NU21-03-00411the Cooperatio Program, research area "Oncology and Haematology"
6 · The paper itself

Abstract

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsLymphoma, Large B-Cell, DiffuseMethotrexateAdultAgedCyclophosphamideDoxorubicinEtoposideFemaleHumansMaleMiddle AgedPrednisoneProspective StudiesRituximabCyclophosphamideDoxorubicinEtoposideMethotrexatePrednisoneR-CHOP protocolRituximabVincristineCNS‐IPICNS prophylaxisCNS relapsediffuse large B‐cell lymphomamethotrexate

Identifiers

PMID42062177
PMCPMC13132674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.